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Ankle-brachialindex(ABI)isanaccuratetooltodiagnoseperipheralarterialdisease.Theaimofthisstudywastoevaluatewhether
ABIisalsoagoodpredictorofrenaloutcomeandcardiovasculareventsinpatientswithchronickidneydisease(CKD).Weenrolled
436 patients with stage 3–5CKD who had not been undergoing dialysis. Patients were stratiﬁed into two groups according to the
ABI value with a cut point of 0.9. The composite renal outcome, including doubling of serum creatinine level and commencement
of dialysis, and the incidence of cardiovascular events were compared between the two groups. After a median follow-up period
of 13 months, the lower ABI group had a poorer composite renal outcome (OR = 2.719, P = 0.015) and a higher incidence of
cardiovascular events (OR = 3.260, P = 0.001). Our ﬁndings illustrated that ABI is a powerful predictor of cardiovascular events
and renal outcome in patients with CKD.
1.Introduction
Chronic kidney disease (CKD) is a growing health concern
worldwide. According to several epidemiologic studies, the
prevalence of CKD ranges from 11.9% to 16.2% in diﬀerent
countries [1–4]. CKD is associated with high cardiovascular
mortality [5], which is the leading cause of mortality in
many developed countries. Furthermore, many patients with
CKD develop end-stage renal disease (ESRD), which is a
tremendous burden on health care systems [6]. Thus, simple
and eﬀective methods are required to identify such high-risk
patientsandtopreventthemfromdevelopingcardiovascular
events or ESRD [7].
The ankle-brachial index (ABI) is a good tool to evaluate
systemic atherosclerosis [8] and the outcome of cardiovas-
cular disease. An ABI less than 0.9 is highly sensitive and
speciﬁc for the diagnosis of peripheral arterial occlusive
disease (PAOD) [9], which is a prominent risk factor for
ischemic heart disease and cardiovascular mortality [10].
The aim of this study was to evaluate whether low ABI is
a good predictive factor for determining renal outcome and
cardiovascular events in patients with CKD.
2.MaterialandMethods
2.1. Study Population. This prospective observational study
was conducted between October 2008 and January 2010 in
a tertiary referral center. We enrolled patients older than
18 years of age with a GFR of less than 60ml/min/1.73m2,
as calculated by the modiﬁcation of diet in renal disease
equation. Patients undergoing renal replacement therapy or2 The Scientiﬁc World Journal
those who had undergone renal transplantation or bilateral
leg amputation were excluded from the study. The study
protocol was approved by the Institutional Review Board
of our hospital. All participants provided written informed
consent.
2.2. ABI Measurement. After enrollment, the subjects’ ABI
was measured at the outpatient clinic. Measurements of ABI
were obtained using an ABI-form device (VP1000; Colin,
Komaki, Japan), which automatically and simultaneously
measures blood pressure in both the arms and the ankles by
usinganoscillometricmethod.TheABIwascalculatedasthe
ratio of the systolic blood pressure of the ankle to that of the
arm.ThelowestABIobtainedfromeitherlegwastakenasthe
patient’s ABI value. The ABI measurement was done once in
each patient.
2.3. Collection of Demographic and Laboratory Data. Demo-
graphic data, including age, gender, diabetes mellitus status,
hypertension status, and use of prescribed antihypertensive
agents, were obtained from the patients’ medical records. A
patient was considered to have hypertension if the systemic
blood pressure was more than 140mmHg or diastolic
blood pressure was more than 90mmHg or if the patient
was currently using antihypertensive agents. A patient was
considered to have diabetes mellitus if the fasting blood
sugar was more than 7mmol/L or if the patient was
using oral antidiabetic agents or insulin. Systemic blood
pressure, diastolic blood pressure, pulse pressure, and body
mass index (BMI) were recorded during the same visit
when ABI was measured. The BMI was calculated as the
ratio of the body weight in kilograms to the square of
height in meters. Laboratory data, including levels of serum
albumin, cholesterol, uric acid, calcium, phosphate, and
hemoglobin, were measured from fasting blood samples.
Urine protein/creatinine ratio (UPCR) was measured from
the ﬁrst morning voiding. These data were acquired within 1
month of the measurement of ABI.
2.4. Study Followup and Endpoints. All participants received
regular followup in our nephrology clinic. Serum creatinine
levels were measured every 3 months to determine the
decline in renal function. The composite renal outcome was
deﬁned as doubling of serum creatinine or commencement
of renal replacement therapy (hemodialysis, peritoneal dial-
ysis, or renal transplantation). Another study outcome was
the occurrence of cardiovascular events, deﬁned as mortality
orhospitalizationbecauseofcerebrovascularevents,myocar-
dialinfarction,congestedheartfailure,orperipheralvascular
diseases.
2.5. Statistical Analysis. All statistical analyses were per-
formed using SPSS 16.0 for Windows (SPSS Inc., Chicago,
Il, USA). Data were expressed as mean ± standard deviation
or as a percentage. For analysis of the determinants of low
ABI, a chi-square test was used for categorical variables, and
an independent t-test was used for continuous variables.
Multivariate forward logistic regression analysis was applied
to identify the independent determinant factors of low
ABI. To determine the inﬂuence of ABI on renal and
cardiovascular outcome, we used the Kaplan-Meier analysis.
Cox regression model was used to evaluate the eﬀect of
presumed risk factors on renal and cardiovascular outcome.
V a r i a b l e sw i t haP value less than 0.1 in univariate Cox
regression analysis were included in a multivariate Cox
regression analysis.
3. Results
In this study, we enrolled 436 patients. The baseline char-
acteristics of the study population are shown in Table 1.
T h em e a na g ew a s7 3 . 4± 10.5 years, 36.9% of the patients
had diabetes mellitus, and 87.4% of the patients were
hypertensive. The prevalence of low ABI was 12.4%, and the
mean GFR was 28.0 ± 13.0ml/min/1.73m2. Patients with
ABI < 0.9 tended to be older and have a higher prevalence
of diabetes and hypertension, higher systolic blood pressure
andpulsepressure,lowerserumalbuminlevel,higherUPCR,
and a higher prevalence of calcium channel blocker usage.
Multivariate logistic regression analysis was performed to
analyze the determinants of low ABI in our subjects. The
results are listed in Table 2.A B I< 0.9 was associated with
old age (OR = 2.020, P = 0.001), low GFR (OR = 0.727,
P = 0.017), diabetes mellitus (OR = 2.360, P = 0.006), and
high pulse pressure (OR = 1.365, P = 0.002).
The median follow-up time of the study was 13 months.
In low ABI group, two patients died (3.7%), where as six
patients died in the ABI > 0.9 group (1.6%). Nine patients
(16.7%) with ABI < 0.9 and sixteen patients (5.0%) with
ABI ≥ 0.9 reached composite renal endpoint, and thirteen
patients (24.1%) with ABI < 0.9 and twenty-three patients
(6.0%) with ABI ≥ 0.9 developed cardiovascular events.
Compared to those with ABI ≥ 0.9, the low ABI group had
poorer composite renal outcome (P = 0.002) and higher
incidence of cardiovascular events (P<0.001), as revealed
by the Kaplan-Meier analysis (Figure 1). In multivariate
Cox regression analyses, low ABI was still an independent
predictive risk factor of composite renal outcome (OR =
2.719, P = 0.015) (Table 3) and cardiovascular events (OR
= 3.260, P = 0.001) (Table 4).
4. Discussion
ABI has been well recognized as a diagnostic index of PAOD
[9] and a marker for atherosclerosis. It has also been shown
to be a good prognostic tool to evaluate the risk of stroke,
myocardial infarction, progression of renal failure, and car-
diovascular death in normal populations [11–14]. Similarly,
ABI has also been shown to be a good marker for predicting
cardiovascular mortality in CKD patients irrespective of
whether they are receiving renal replacement therapy [15,
16]. However, its power to predict a decline in renal function
in patients with CKD has not been well studied. Our analysis
revealed that low ABI is associated with a rapid decline in
renal function. In a multivariate Cox regression analysis,
patients with lower ABI had a 2.72-fold higher risk forThe Scientiﬁc World Journal 3
Table 1: Baseline characteristics of study participants grouped by ABI.
Characteristic All patients
N = 436
ABI < 0.9
N = 54
ABI  0.9
N = 382 P value
Age (year) 73.4 ±10.57 7 .7 ±7.47 2 .8 ±10.7 <0.001
Male gender (%) 77.8 85.2 76.7 0.161
Diabetes mellitus (%) 36.9 57.4 34.0 0.001
Hypertension (%) 87.4 96.3 86.1 0.035
Mean ABI 1.06 ±0.17 0.71 ±0.15 1.11 ±0.09 <0.001
Systolic BP (mmHg) 144.3 ±20.2 152.6 ±22.5 143.1 ±19.6 0.001
Diastolic BP (mmHg) 77.5 ±10.87 7 .2 ±11.87 7 .5 ±10.7 0.835
P u l s ep r e s s u r e( m m H g ) 6 6 .8 ±15.07 5 .4 ±17.06 5 .6 ±14.3 <0.001
BMI 24.8 ±3.72 4 .7 ±3.52 4 .8 ±3.8 0.943
Albumin level (g/L) 41.1 ±4.33 9 .8 ±4.44 1 .3 ±4.3 0.014
Hemoglobin level (g/L) 115.1 ±18.4 113.7 ±18.2 115.3 ±18.5 0.563
Cholesterol level (mmol/L) 4.41 ±0.96 4.29 ±0.76 4.42 ±0.99 0.386
Uric acid level (μmol/L) 389.4 ±104.3 413.2 ±100.1 386.1 ±104.6 0.074
Calcium level (mmol/L) 2.27 ±0.12 2.25 ±0.12 2.27 ±0.13 0.326
Phosphate (mmol/L) 1.16 ±0.25 1.17 ± 0.23 1.16 ±0.26 0.654
UPCR (g/g) 1.6 ±2.72 .5 ± 3.51 .5 ±2.5 0.041
GFR (ml/min/1.73m2)2 8 .0 ±13.02 4 .8 ±11.72 8 .4 ±13.2 0.057
CKD stage 0.219
Stage 3 40.4 29.6 41.9
Stage 4 40.4 46.3 39.5
Stage 5 19.3 24.1 18.6
Medication
ACE-I or ARB (%) 46.1 51.9 45.3 0.365
CCB (%) 50.5 66.7 48.2 0.011
β-blocker (%) 17.4 22.2 16.8 0.321
Statin (%) 21.8 27.8 20.9 0.255
ABI: ankle-brachial index, BP: blood pressure, BMI: body mass index, UPCR: urine protein/creatinine ratio, GFR: glomerular ﬁltration rate, CKD: chronic
kidney disease, ACE-I: angiotensin converting enzyme inhibitor, ARB: angiotensin II receptor blocker, CCB: calcium channel blocker.
Table 2: Multivariate logistic regression analysis of determinant
factors of low ABI in patients with chronic kidney disease.
Hazard
ratio
95% CI
Lower
95% CI
Upper P value
Age (per 10 years) 2.020 1.351 3.021 0.001
G F R( p e r1 0m l / m i n / 1 . 7 3m 2) 0.727 0.560 0.944 0.017
Diabetes mellitus 2.360 1.278 4.357 0.006
Pulse pressure (per 10mmHg) 1.365 1.122 1.662 0.002
GFR: glomerular ﬁltration rate, CI: conﬁdence interval.
rapid deterioration of renal function. Renal failure is a
well-known risk factor for systemic atherosclerosis, which
can cause various cardiovascular diseases. However, recent
studies suggest that atherosclerosis, in turn, may exacerbate
renal failure. O’Hare et al. reported that a lower ABI value
was related to an increase in serum creatinine level over time
inanormalpopulation[14].Feringaetal.alsodemonstrated
that every 0.1 decrease in the ABI level was associated with
a 1.43-fold increase in the risk of development of ESRD in
patients with PAOD [13]. In this study, we found that ABI
was an independent prognostic factor for the decline in renal
function in patients with CKD, irrespective of the underlying
cause of renal disease, such as diabetes or hypertension.
Therefore, this ﬁnding suggests that systemic atherosclerosis
may be implicated in a common pathogenic pathway in renal
dysfunction.
In addition to progressive renal failure, cardiovascular
diseases are a major concern in patients with CKD. Several
studies have implicated poor renal function as a factor in
increasing cardiovascular events and mortality [5, 17, 18].
Among CKD patients, those with low ABI have a higher
rate of cardiovascular events and mortality [15, 16, 19].
Our results are consistent with this observation. Twenty-four
percent of patients with low ABI developed cardiovascular
events during a mean follow-up period of 13 months.
This translates into a 3.3-fold higher risk for developing
cardiovascular events in patients with ABI < 0.9 than in
patients with ABI ≥ 0.9. Aggressive treatment may be needed
to prevent cardiovascular events in this high-risk group.4 The Scientiﬁc World Journal
Table 3: Cox proportional analysis for composite renal outcome.
Parameter Univariate Multivariate (forward)
Hazard ratio P value Hazard ratio P value
Age (per 10 years) 0.808 (0.591 to 1.104) 0.180
Male versus female 0.590 (0.267 to 1.304) 0.192
Hypertension 1.968 (0.467 to 8.296) 0.356
Diabetes mellitus 1.893 (0.901 to 3.976) 0.092
PAOD 3.285 (1.486 to 7.262) 0.003 2.719 (1.214 to 6.092) 0.015
G F R( p e r1 0m l / m i n / 1 . 7 3m 2) 0.271 (0.167 to 0.441) <0.001 0.280 (0.162 to 0.484) <0.001
Systolic BP (per 10mmHg) 1.241 (1.054 to 1.463) 0.010
Diastolic BP (per 10mmHg) 1.454 (1.053 to 2.007) 0.023
Pulse pressure (per 10mmHg) 1.235 (0.987 to 1.544) 0.065
BMI (kg/m2) 0.989 (0.896 to 1.092) 0.833
Albumin (per 1g/L) 0.822 (0.772 to 0.875) <0.001 0.890 (0.812 to 0.975) 0.013
Hb (per 1g/L) 0.954 (0.933 to 0.976) <0.001
Cholesterol (per 1mmol/L) 1.224 (0.852 to 1.758) 0.274
Uric acid (per 1μmol/L) 1.003 (1.000 to 1.006) 0.073
Calcium (per 1mmol/L) 0.007 (0.001 to 0.095) <0.001
Phosphate (per 1mmol/L) 4.090 (2.117 to 7.899) <0.001
UPCR (per 1g/g) 1.291 (1.216 to 1.370) <0.001 1.115 (1.010 to 1.231) 0.030
PAOD: peripheral arterial occlusive disease, GFR: glomerular ﬁltration rate, BMI: body mass index, UPCR: urine protein/urine creatinine ratio.
Table 4: Cox proportional analysis for cardiovascular events.
Parameter Univariate Multivariate (forward)
Hazard ratio P value Hazard ratio P value
Age (per 10 years) 2.135 (1.356 to 3.364) 0.001 2.073 (1.297 to 3.311) 0.002
Male versus female 1.191 (0.521 to 2.719) 0.679
Hypertension 1.721 (0.528 to 5.613) 0.368
Diabetes mellitus 1.312 (0.676 to 2.547) 0.423
PAOD 4.402 (2.230 to 8.691) <0.001 3.260 (1.644 to 6.463) 0.001
G F R( p e r1 0m l / m i n / 1 . 7 3m 2) 0.920 (0.714 to 1.184) 0.516
Systolic BP (per 10mmHg) 1.136 (0.976 to 1.323) 0.100
Diastolic BP (per 10mmHg) 1.085 (0.805 to 1.463) 0.591
Pulse pressure (per 10mmHg) 1.209 (0.988 to 1.480) 0.065
BMI (kg/m2) 1.016 (0.930 to 1.109) 0.726
Albumin (per 1g/L) 0.922 (0.868 to 0.980) 0.009
Hb (per 1g/L) 1.005 (0.987 to 1.023) 0.607
Cholesterol (per 1mmol/L) 1.098 (0.759 to 1.589) 0.620
Uric acid (per 1μmol/L) 1.004 (1.002 to 1.007) 0.001 1.004 (1.002 to 1.007) 0.002
Calcium (per 1mmol/L) 2.669 (0.191 to 37.29) 0.466
Phosphate (per 1mmol/L) 1.400 (0.451 to 4.349) 0.561
UPCR (per 1g/g) 1.095 (1.010 to 1.186) 0.027
PAOD: peripheral arterial occlusive disease, BMI: body mass index, UPCR: urine protein/urine creatinine ratio.
Although results from our study suggest that ABI is
a good indicator of renal and cardiovascular outcomes in
patients with CKD stage 3–5, our study population was
selected from a single center, and hence may not be fully
representative of the CKD population at large. Therefore,
similar studies are required to conﬁrm the predictive power
of ABI in other populations. Furthermore, in our study,
we deﬁned cardiovascular events as either hospitalization
or death due to cardiovascular disease. Since hospitalization
may partly reﬂect disease severity and has been used asThe Scientiﬁc World Journal 5
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Figure 1: The relationship between ABI and composite renal end-
point and cardiovascular events. Kaplan-Meier’s curves with log-
rank tests of (a) freedom from composite renal endpoint and (b)
freedom from cardiovascular events in patients with chronic kidney
disease stratiﬁed according to the level of ankle-brachial index
(ABI).
a surrogate endpoint in several large clinical trials, we
thought that this would be an adequate deﬁnition of
cardiovascular endpoint. However, since hospital admission
criteria for cardiovascular disease may diﬀer from place to
place, redeﬁning a cardiovascular event as cardiovascular
mortality may reduce the variability introduced by such
diﬀerences. In our follow-up period, we observed very
few cardiovascular mortalities. Therefore, extended follow-
up studies are needed to determine whether deﬁning a
cardiovasculareventascardiovascularmortalitymightbetter
deﬁne the association between ABI and cardiovascular
events. Similarly, because of diﬀerences in age, gender, and
baseline renal function in our study population, deﬁning
renal endpoint as a doubling of serum creatinine may
not be as accurate as deﬁning it as a decline in GFR.
However, since all the enrolled subjects had a GFR less
than 60ml/min/1.73m2, a decline in GFR of more than
4ml/min/1.73m2 per year, which is the deﬁnition for rapid
decline in renal function as in K/DOQI guideline [20], was
less indicative of disease severity than a doubling of serum
creatininelevelinthefollow-upperiod.Thus,webelievethat
our deﬁnition of renal outcome is appropriate.
5. Conclusion
Our study shows that patients with stage 3–5 CKD who
have a lower ABI have a rapid decline in renal function and
a high incidence of cardiovascular events. Since ESRD and
cardiovascular diseases are major risks in patients with CKD,
we suggest that ABI, a noninvasive and convenient tool to
diagnose PAOD and systemic atherosclerosis, be used in all
these patients.
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